Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Digital1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- Eur J Pharmacol1
Search Results
Sort by
- Bookeditors-in-chief, John W. Frymoyer, Sam W. Wiesel ; associate editors, Howard S. An ... [et al.].Digital Access Ovid 2004
- ArticleArregui A, Emson PC, Spokes EG.Eur J Pharmacol. 1978 Nov 01;52(1):121-4.The substantia nigra of Huntington's disease brains shows a 78% reduction in angiotensin-converting enzyme activity in the pars reticulata and a 48% reduction in the pars compacta. The nucleus accumbens shows a 28% reduction in converting enzyme activity. In the rat, after intrastriatal injections of kainic acid (2.5 microgram), an agent which selectively destroys neuronal cell bodies, there is a 55% reduction in angiotensin-converting enzyme activity in the ipsilateral substantia nigra. Both human and animal data suggest that a major part of the angiotensin-converting enzyme in the substantia nigra is localized in nerve terminals whose cell bodies originate in the striatum.